News
We send the latest information from SMC Laboratories.
University of Nebraska’s publication on Biochemistry.
SMC announced that University of Nebraska has published the results of a study using STAM™ model on Biochemistry. Title: “A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease”
Genomics Institute of the Novartis Research Foundation’s publication on Hepatology Communications.
SMC announced that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model on Hepatology Communications. Title: “Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with the Antioxidative Gene Expression Profile in Rodents”
FDA-National Center for Toxicological Research’s publication in Frontiers in Genetics.
SMC announced that FDA-National Center for Toxicological Research (NCTR) published the results of a study using STAM™ model in Frontiers in Genetics. Title: Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis Read more…https://www.ncbi.nlm.nih.gov/pubmed/31191608
Enanta Pharmaceuticals, Inc’s publication on the International Journal of Gastroenterology.
SMC announces that Enanta Pharmaceuticals, Inc. has published the results of a study using the STAM™ model in the International Journal of Gastroenterology. Title: Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis Read more…. http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=282&doi=10.11648/j.ijg.20190301.12
Kanagawa University of Human Services’ publication on Experimental Animals.
SMC announced that Kanagawa University of Human Services has published the results of a study using STAM™ model on Experimental Animals. Title: “Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/31155606
Osaka Medical College’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that Osaka Medical College presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Influence of the O-GlcNAc Modification in Hepatic Carcinogenesis by Non-alcoholic Fatty Liver Disease”
TSUMURA & Co.’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that TSUMURA & Co. presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Change of Gut Microbiome after Treatment with the Traditional Japanese Medicine Daisaikoto is Associated with Improved Liver Steatosis in a Non-alcoholic Fatty Liver Mouse Model”
Phenex Pharmaceuticals AG’s presentation at EASL the International Liver CongressTM 2019 in Vienna, Austria.
SMC announced that Phenex Pharmaceuticals AG presented results of a study using STAM™ model at oral presentation at EASL the International Liver CongressTM 2019 in Vienna, Austria, April 10-19, 2019. Title: LXR inverse agonists reduce steatosis and fibrosis in the STAM™ mouse model but also improve insulin sensitivity in a high fat diet mouse clamp…
Pharmaxis Ltd’s publication on Journal of Cellular and Molecular Medicine.
SMC announced that Pharmaxis Ltd has published the results of a study using STAM™ model on Journal of Cellular and Molecular Medicine. Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis” Read more….https://www.ncbi.nlm.nih.gov/pubmed/30536539
Publication on Scientific Reports.
SMC announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Scientific Reports: Title: “Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/30850637